$558 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 64 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 93.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMMU | Buy | IMMUNOMEDICS INC | $94,193,000 | +566.7% | 6,737,706 | +321.1% | 16.88% | +326.9% |
| IWM | Buy | ISHARES TRput | $68,904,000 | +34.0% | 465,000 | +27.4% | 12.35% | -14.2% |
| XBI | Buy | SPDR SERIES TRUSTput | $48,479,000 | +64.3% | 560,000 | +46.5% | 8.69% | +5.2% |
| ASMB | Sell | ASSEMBLY BIOSCIENCES INC | $34,920,000 | +64.2% | 1,000,000 | -2.9% | 6.26% | +5.1% |
| VCYT | Buy | VERACYTE INC | $28,898,000 | +12.6% | 3,295,111 | +7.0% | 5.18% | -27.9% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $26,597,000 | +6.0% | 3,431,809 | +0.5% | 4.77% | -32.2% |
| Buy | INTEC PHARMA LTD JERUSALEM | $24,382,000 | +969.4% | 2,724,283 | +581.1% | 4.37% | +584.8% | |
| IRIX | Buy | IRIDEX CORP | $18,740,000 | +9.1% | 2,000,000 | +15.1% | 3.36% | -30.2% |
| ASND | Sell | ASCENDIS PHARMA A Ssponsored adr | $18,125,000 | -29.4% | 500,000 | -45.9% | 3.25% | -54.8% |
| EDGE | Sell | EDGE THERAPEUTICS INC | $13,449,000 | -12.9% | 1,253,394 | -16.7% | 2.41% | -44.2% |
| KDMN | New | KADMON HLDGS INC | $11,167,000 | – | 3,333,333 | +100.0% | 2.00% | – |
| CEMI | Buy | CHEMBIO DIAGNOSTICS INC | $10,672,000 | +29.9% | 1,721,299 | +26.7% | 1.91% | -16.8% |
| IMMU | New | IMMUNOMEDICS INCcall | $9,332,000 | – | 667,500 | +100.0% | 1.67% | – |
| ZGNX | Sell | ZOGENIX INC | $8,763,000 | +100.3% | 250,000 | -17.1% | 1.57% | +28.3% |
| DBVT | New | DBV TECHNOLOGIES S Aput | $8,488,000 | – | 200,000 | +100.0% | 1.52% | – |
| DBVT | Buy | DBV TECHNOLOGIES S Asponsored adr | $8,148,000 | +111.7% | 192,000 | +78.2% | 1.46% | +35.6% |
| EVH | Buy | EVOLENT HEALTH INCcl a | $8,010,000 | +12.6% | 450,000 | +60.4% | 1.44% | -27.9% |
| VRAY | Buy | VIEWRAY INC | $7,672,000 | +72.8% | 1,331,983 | +94.1% | 1.38% | +10.6% |
| CLVS | New | CLOVIS ONCOLOGY INCcall | $6,592,000 | – | 80,000 | +100.0% | 1.18% | – |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $6,404,000 | -8.2% | 170,000 | -32.0% | 1.15% | -41.2% |
| JNJ | Buy | JOHNSON & JOHNSONput | $5,850,000 | +10.5% | 45,000 | +12.5% | 1.05% | -29.2% |
| ZGNX | Buy | ZOGENIX INCput | $5,608,000 | +286.8% | 160,000 | +60.0% | 1.00% | +147.5% |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS | $5,221,000 | +456.6% | 996,300 | +490.6% | 0.94% | +255.9% |
| NVTA | Buy | INVITAE CORP | $4,947,000 | +415.8% | 528,000 | +426.5% | 0.89% | +231.0% |
| ARGX | Buy | ARGENX SEsponsored adr | $4,890,000 | +50.8% | 216,255 | +41.5% | 0.88% | -3.4% |
| CASM | Buy | CAS MED SYS INC | $4,686,000 | -15.1% | 5,093,276 | +7.0% | 0.84% | -45.6% |
| FOLD | New | AMICUS THERAPEUTICS INC | $4,524,000 | – | 300,000 | +100.0% | 0.81% | – |
| FXI | New | ISHARES TRput | $4,404,000 | – | 100,000 | +100.0% | 0.79% | – |
| VIVE | Buy | VIVEVE MED INC | $4,335,000 | -15.0% | 827,340 | +16.5% | 0.78% | -45.6% |
| SGEN | New | SEATTLE GENETICS INCput | $3,809,000 | – | 70,000 | +100.0% | 0.68% | – |
| Sell | NABRIVA THERAPEUTICS PLC | $3,276,000 | -66.9% | 400,000 | -57.7% | 0.59% | -78.8% | |
| TOCA | New | TOCAGEN INC | $3,129,000 | – | 251,112 | +100.0% | 0.56% | – |
| QTNT | Buy | QUOTIENT LTD | $2,806,000 | -30.8% | 569,145 | +3.3% | 0.50% | -55.7% |
| FENC | New | FENNEC PHARMACEUTICALS INC | $2,773,000 | – | 250,000 | +100.0% | 0.50% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INCcall | $2,637,000 | – | 70,000 | +100.0% | 0.47% | – |
| LCI | Buy | LANNET INCput | $2,352,000 | +28.7% | 127,500 | +42.3% | 0.42% | -17.8% |
| FOLD | New | AMICUS THERAPEUTICS INCcall | $2,277,000 | – | 151,000 | +100.0% | 0.41% | – |
| SGEN | New | SEATTLE GENETICS INCcall | $2,176,000 | – | 40,000 | +100.0% | 0.39% | – |
| RMTI | New | ROCKWELL MED INCput | $2,140,000 | – | 250,000 | +100.0% | 0.38% | – |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $2,104,000 | – | 15,000 | +100.0% | 0.38% | – |
| CNC | New | CENTENE CORP DELput | $1,935,000 | – | 20,000 | +100.0% | 0.35% | – |
| NITE | New | NIGHTSTAR THERAPEUTICS PLCadr | $1,920,000 | – | 100,000 | +100.0% | 0.34% | – |
| GOGO | Buy | GOGO INCput | $1,594,000 | +176.3% | 135,000 | +170.0% | 0.29% | +77.6% |
| EVH | New | EVOLENT HEALTH INCcall | $1,477,000 | – | 83,000 | +100.0% | 0.26% | – |
| AIMT | New | AIMMUNE THERAPEUTICS INC | $1,451,000 | – | 58,525 | +100.0% | 0.26% | – |
| CBMXW | New | COMBIMATRIX CORPORATION*w exp 03/18/202 | $1,411,000 | – | 564,200 | +100.0% | 0.25% | – |
| AXDX | New | ACCELERATE DIAGNOSTICS INCput | $1,347,000 | – | 60,000 | +100.0% | 0.24% | – |
| ALIM | ALIMERA SCIENCES INC | $1,315,000 | -2.9% | 974,318 | 0.0% | 0.24% | -37.7% | |
| EVTC | New | EVERTEC INCput | $1,090,000 | – | 68,800 | +100.0% | 0.20% | – |
| PTLA | New | PORTOLA PHARMACEUTICALS INCput | $1,081,000 | – | 20,000 | +100.0% | 0.19% | – |
| RARX | Sell | RA PHARMACEUTICALS INC | $1,044,000 | -85.1% | 71,500 | -80.9% | 0.19% | -90.5% |
| TDOC | New | TELADOC INCput | $995,000 | – | 30,000 | +100.0% | 0.18% | – |
| GKOS | Buy | GLAUKOS CORPput | $990,000 | -0.9% | 30,000 | +24.5% | 0.18% | -36.8% |
| AMAG | New | AMAG PHARMACEUTICALS INCput | $923,000 | – | 50,000 | +100.0% | 0.16% | – |
| CBMX | New | COMBIMATRIX CORPORATION | $839,000 | – | 111,912 | +100.0% | 0.15% | – |
| MDXG | New | MIMEDX GROUP INCput | $832,000 | – | 70,000 | +100.0% | 0.15% | – |
| MNKD | Buy | MANNKIND CORPput | $760,000 | +1552.2% | 350,000 | +983.6% | 0.14% | +946.2% |
| LXRX | New | LEXICON PHARMACEUTICALS INCput | $492,000 | – | 40,000 | +100.0% | 0.09% | – |
| DBVT | New | DBV TECHNOLOGIES S Acall | $382,000 | – | 9,000 | +100.0% | 0.07% | – |
| AXGT | New | AXOVANT SCIENCES LTDcall | $140,000 | – | 20,300 | +100.0% | 0.02% | – |
| OTIC | New | OTONOMY INCcall | $57,000 | – | 17,500 | +100.0% | 0.01% | – |
| ONS | ONCOBIOLOGICS INC | $40,000 | +37.9% | 29,082 | 0.0% | 0.01% | -12.5% | |
| ONSIW | ONCOBIOLOGICS INC*w exp 02/18/201 | $12,000 | -29.4% | 96,833 | 0.0% | 0.00% | -60.0% | |
| ONSIZ | ONCOBIOLOGICS INC*w exp 05/18/201 | $5,000 | -44.4% | 96,833 | 0.0% | 0.00% | -66.7% | |
| Exit | ESSA PHARMA INC | $0 | – | -442,000 | -100.0% | -0.07% | – | |
| SGMO | Exit | SANGAMO THERAPEUTICS INCput | $0 | – | -30,000 | -100.0% | -0.07% | – |
| Exit | NEURODERM LTDput | $0 | – | -10,000 | -100.0% | -0.08% | – | |
| IMGN | Exit | IMMUNOGEN INCcall | $0 | – | -50,000 | -100.0% | -0.10% | – |
| CYTK | Exit | CYTOKINETICS INCput | $0 | – | -40,000 | -100.0% | -0.14% | – |
| MYGN | Exit | MYRIAD GENETICS INCput | $0 | – | -19,400 | -100.0% | -0.14% | – |
| ACOR | Exit | ACORDA THERAPEUTICS INCput | $0 | – | -30,000 | -100.0% | -0.16% | – |
| OMER | Exit | OMEROS CORPput | $0 | – | -40,000 | -100.0% | -0.22% | – |
| VSAR | Exit | VERSARTIS INCput | $0 | – | -49,100 | -100.0% | -0.24% | – |
| INSM | Exit | INSMED INCput | $0 | – | -50,000 | -100.0% | -0.24% | – |
| ZIOP | Exit | ZIOPHARM ONCOLOGY INCput | $0 | – | -150,000 | -100.0% | -0.26% | – |
| VCYT | Exit | VERACYTE INCcall | $0 | – | -160,000 | -100.0% | -0.37% | – |
| REPH | Exit | RECRO PHARMA INC | $0 | – | -200,500 | -100.0% | -0.40% | – |
| SPNC | Exit | SPECTRANETICS CORPput | $0 | – | -40,000 | -100.0% | -0.43% | – |
| EXEL | Exit | EXELIXIS INCput | $0 | – | -70,000 | -100.0% | -0.48% | – |
| CLVS | Exit | CLOVIS ONCOLOGY INC | $0 | – | -20,000 | -100.0% | -0.52% | – |
| WBMD | Exit | WEBMD HEALTH CORP | $0 | – | -33,000 | -100.0% | -0.54% | – |
| AERI | Exit | AERIE PHARMACEUTICALS INCput | $0 | – | -40,000 | -100.0% | -0.59% | – |
| Exit | NEURODERM LTD | $0 | – | -72,866 | -100.0% | -0.61% | – | |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INCcall | $0 | – | -324,000 | -100.0% | -0.67% | – |
| JUNO | Exit | JUNO THERAPEUTICS INCput | $0 | – | -80,000 | -100.0% | -0.67% | – |
| ACRS | Exit | ACLARIS THERAPEUTICS INC | $0 | – | -90,000 | -100.0% | -0.68% | – |
| TSRO | Exit | TESARO INC | $0 | – | -23,700 | -100.0% | -0.93% | – |
| ASMB | Exit | ASSEMBLY BIOSCIENCES INCcall | $0 | – | -185,000 | -100.0% | -1.07% | – |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -165,690 | -100.0% | -1.11% | – |
| KITE | Exit | KITE PHARMA INC | $0 | – | -75,000 | -100.0% | -2.18% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.